奈达铂
医学
多西紫杉醇
食管胃十二指肠镜检查
经皮内镜胃造口术
化疗
食管癌
内科学
癌症
血液透析
吞咽
肿瘤科
外科
内窥镜检查
顺铂
经济
财务
PEG比率
作者
Tetsuji Miura,Y Hosojima,Jun Nakamura,Shunsuke Yamada,Yukie Nakazawa,Yuichiro Ozeki,Masayuki Yanagi,H Yamazaki,T Takahashi
摘要
An 82-year-old man was admitted for recurrent and unresectable esophageal cancer. His performance status was grade 2, although he was on hemodialysis due to chronic renal failure since 2003. Esophagogastroduodenoscopy revealed stenosis of esophagus by the recurrent tumor. After percutaneous endoscopic gastrostomy, he received biweekly combination chemotherapy with docetaxel (18 mg/m(2)) and nedaplatin (16 mg/m(2)). Hemodialysis was carried out one hour after termination of nedaplatin infusion. As severe adverse reactions due to anticancer-chemotherapy were not encountered, he could receive four courses of chemotherapy in our outpatient clinic. Difficulty in swallowing improved after the second course was finished. Finally, he died of acute myocardial infarction. In conclusion, combination chemotherapy with docetaxel and nedaplatin can be safely carried out for a patient with recurrent and unresectable esophageal cancer even on hemodialysis by appropriate down-dosing of anticancer agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI